Adjudicatário
1 HEALTH ECONOMICS ARTICLE - BASED IN PPT AND IN THE INITIAL DRAFT. COST-EFFEXTIVENESS OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT FOR HER-2 POSITIVE…
Contraparte: Instituto Português de Oncologia do Porto Francisco Gentil
9 044 €